Personalis, Inc. Common Stock
PSNL
$16.88
+6.77%
Personalis, Inc. is a genomic sequencing and analytics company that supports the development of personalized cancer vaccines and next-generation cancer immunotherapies. It operates as a niche player in the precision oncology diagnostics industry, offering products like ImmunoID NeXT and NeXT Personal. The current investor narrative centers on the company's turnaround potential, driven by a recent surge in stock price amid improving revenue trends and strategic partnerships, though profitability remains elusive.…
PSNL
Personalis, Inc. Common Stock
$16.88
PSNL 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Personalis, Inc. Common Stock's 12-month outlook, with a consensus price target around $13.88 and implied upside of -17.8% versus the current price.
Average Target
$13.88
0 analysts
Implied Upside
-17.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$10 - $16
Analyst target range
Seven analysts cover Personalis, with a consensus recommendation of 'Strong Buy' (mean 1.43 on a 1-5 scale). The average target price is $12.57, implying a downside of -18.3% from the current price of $15.39. The target range spans from $10.00 (low) to $18.00 (high). The high target of $18.00 assumes successful commercialization of NeXT Personal and margin expansion, while the low target of $10.00 reflects risks of continued cash burn and competitive pressures. Recent ratings from Morgan Stanley (Equal Weight), BTIG (Buy), Needham (Buy), and Guggenheim (Buy) show a bullish tilt, though the average target below the current price suggests the stock has overshot near-term fundamentals. The wide spread between low and high targets ($8.00) indicates high uncertainty about the company's trajectory.
Bulls vs Bears: PSNL Investment Factors
Personalis presents a high-risk, high-reward investment case. On the bullish side, the company has a strong balance sheet, a consensus 'Strong Buy' rating, and expectations of significant revenue growth driven by its NeXT Personal product. However, the bear case is equally compelling: persistent losses, negative free cash flow, a dramatic decline in gross margins to 1.8%, and a stock price that already exceeds the average analyst target by 22.5%. The single most important tension is whether the company can execute on its growth strategy to achieve the revenue estimates that justify its current valuation. If revenue growth accelerates and margins improve, the stock could re-rate higher; if not, the high trailing PS ratio of 42.9x leaves little room for error.
Bullish
- Strong Revenue Growth Expected: Analysts estimate revenue of $227.4 million for the current fiscal year, implying a forward PS ratio of ~3.1x, which is reasonable if growth materializes. This represents a significant increase from the trailing twelve-month revenue of ~$63 million, driven by the launch of NeXT Personal and strategic partnerships.
- Low Debt and High Liquidity: Personalis has a debt-to-equity ratio of only 0.15 and a current ratio of 6.76, indicating a strong balance sheet with minimal leverage and ample short-term assets to cover liabilities. This financial stability reduces bankruptcy risk and provides a cushion for ongoing operations.
- Strong Analyst Consensus: The stock has a consensus 'Strong Buy' rating from 7 analysts, with a mean recommendation of 1.43 on a 1-5 scale. The high analyst target of $18.00 implies potential upside of 17% from the current price of $15.39, reflecting optimism about the company's turnaround.
- Momentum and Relative Strength: The stock has gained 137.5% over the past year and 128.7% over the past three months, vastly outperforming the S&P 500's 18.35% and 4.67% respectively. This strong relative strength suggests positive investor sentiment and potential for continued momentum.
Bearish
- Persistent Losses and Cash Burn: The company reported a net loss of $30.03 million in Q1 2026, with a net margin of -194.1%. Free cash flow was negative $25.67 million in the quarter and -$84.65 million over the trailing twelve months, indicating significant cash burn that may require additional financing.
- Declining Gross Margin: Gross margin plummeted to 1.8% in Q1 2026 from 27.6% in Q2 2025, a dramatic decline that suggests cost pressures or unfavorable product mix. This raises concerns about the company's ability to achieve profitability even with revenue growth.
- Stock Trades Above Average Target: The current price of $15.39 is 22.5% above the average analyst target of $12.57, implying the stock is overvalued relative to near-term fundamentals. The low target of $10.00 suggests a potential downside of 35% from current levels.
- High Valuation on Trailing Sales: The trailing PS ratio of 42.9x is near the upper end of its historical range (2.8x to 51.3x), indicating that optimistic growth expectations are already priced in. Any disappointment in revenue growth could lead to multiple compression.
PSNL Technical Analysis
Personalis is in a strong uptrend, with the stock up 137.5% over the past year and currently trading at $15.39, which is 93.9% of its 52-week range ($3.84–$16.39). This positioning near the highs suggests robust momentum but also potential overextension, as the stock has rallied sharply from its lows. The 1-year price change of 137.5% significantly outperforms the S&P 500's 18.35% gain, indicating strong relative strength. Short-term momentum is accelerating dramatically: the 1-month price change is +57.8% and the 3-month change is +128.7%, both far exceeding the S&P 500's 0.31% and 4.67% respectively. This divergence from the broader market suggests company-specific catalysts are driving the rally, though the pace raises caution about a potential pullback. The stock's beta of 2.243 implies it is 124% more volatile than the market, amplifying both upside and downside risks. Key support lies near the 52-week low of $3.84, while resistance is at the 52-week high of $16.39. A breakout above $16.39 would signal continued bullish momentum, while a breakdown below recent support near $10 could indicate a trend reversal.
Beta
2.29
2.29x market volatility
Max Drawdown
-55.2%
Largest decline past year
52-Week Range
$5-$17
Price range past year
Annual Return
+263.8%
Cumulative gain past year
| Period | PSNL Return | S&P 500 |
|---|---|---|
| 1m | +25.6% | +1.9% |
| 3m | +99.3% | +2.3% |
| 6m | +103.9% | +10.6% |
| 1y | +263.8% | +19.5% |
| ytd | +115.0% | +11.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PSNL Fundamental Analysis
Revenue has been volatile but shows recent improvement: Q1 2026 revenue was $15.47 million, down 24.9% year-over-year from $20.61 million in Q1 2025. However, sequentially, revenue grew from $14.50 million in Q3 2025 and $17.35 million in Q4 2025, indicating a potential stabilization. The company remains unprofitable, with a net loss of $30.03 million in Q1 2026 and a net margin of -194.1%. Gross margin was just 1.8% in Q1 2026, a sharp decline from 27.6% in Q2 2025, reflecting cost pressures or product mix shifts. Operating margin was -207.9%, highlighting significant operating leverage challenges. The balance sheet shows a debt-to-equity ratio of 0.15 and a current ratio of 6.76, indicating low leverage and ample liquidity. However, free cash flow was negative $25.67 million in Q1 2026, and trailing twelve-month free cash flow was -$84.65 million, meaning the company is burning cash and relies on external financing (e.g., $21.23 million in common stock issued in Q1 2026). ROE is -31.1%, reflecting persistent losses.
Quarterly Revenue
$15472000.0B
2026-03
Revenue YoY Growth
-24.9%
YoY Comparison
Gross Margin
1.8%
Latest Quarter
Free Cash Flow
$-84648000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PSNL Overvalued?
Since net income is negative, we use the price-to-sales (PS) ratio. The trailing PS ratio is 42.9x based on historical data, but the current market cap of $710 million divided by trailing twelve-month revenue (approximately $63 million) yields a PS of ~11.3x. The forward PS is not directly provided but implied by estimated revenue of $227.4 million, giving a forward PS of ~3.1x. The gap between trailing and forward PS suggests the market expects significant revenue growth. Compared to the industry average PS (not provided), the stock's PS of 42.9x (trailing) appears extremely high, but the forward PS of 3.1x is more reasonable if growth materializes. Historically, the PS ratio has ranged from 2.8x (Q2 2024) to 51.3x (Q2 2021). The current trailing PS of 42.9x is near the upper end of its historical range, indicating optimistic growth expectations are priced in. The PB ratio of 2.72x is also elevated versus historical lows near 0.39x in Q3 2023, suggesting the market is pricing in a turnaround.
PE
-8.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-8.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Personalis faces significant financial risks due to its persistent unprofitability and cash burn. The company reported a net loss of $30.03 million in Q1 2026, with a net margin of -194.1%, and free cash flow was negative $25.67 million in the same quarter. Over the trailing twelve months, free cash flow was -$84.65 million, indicating the company is consuming cash rapidly. While the balance sheet shows low debt (debt-to-equity of 0.15) and high liquidity (current ratio of 6.76), the cash burn rate could necessitate additional equity financing, diluting existing shareholders. The dramatic decline in gross margin from 27.6% in Q2 2025 to 1.8% in Q1 2026 is a major red flag, suggesting cost pressures or a shift to lower-margin products that could delay profitability.
Market & Competitive Risks: The stock's valuation is stretched on a trailing basis, with a PS ratio of 42.9x near the upper end of its historical range. This leaves it vulnerable to multiple compression if growth disappoints. The stock has a beta of 2.243, making it highly sensitive to market downturns. Competitive pressures in the precision oncology diagnostics space could erode market share or pricing power. The recent surge of 137.5% over the past year may have priced in optimistic expectations, and any negative news could trigger a sharp correction. The lack of recent news in the provided data means we cannot assess specific competitive developments, but the industry is crowded with players like Guardant Health and Natera.
Worst-Case Scenario: In a worst-case scenario, revenue growth fails to materialize, gross margins remain depressed, and the company continues to burn cash, leading to a loss of investor confidence. The stock could fall to its 52-week low of $3.84, representing a 75% decline from the current price of $15.39. This scenario could be triggered by a failed product launch, loss of a key partnership, or a broader market sell-off that disproportionately affects high-beta stocks. The analyst low target of $10.00 implies a 35% downside, but the 52-week low suggests even deeper losses are possible if fundamentals deteriorate.